Navigation Links
Fisher BioServices Intensifies Commitment for Cell Therapy Companies in Clinical Trials and Approaching Commercialization
Date:9/5/2013

Rockville, Maryland (PRWEB) September 05, 2013

Fisher BioServices Inc., a leading provider of biorepository/biobanking and ultra cold chain logistics services, announced that Dan O’Donnell, Associate Director of Cell Therapy Logistics, will speak at three upcoming industry conferences. Mr. O’Donnell, who is widely known for his expertise on ultra cold chain distribution and regulatory compliance in transporting biologics and cryogenically frozen cell-based therapeutics, has been invited to present at the International Society for Cellular Therapy (ISCT) North America Regional Meeting in Philadelphia, Pennsylvania (September 8–11), the Stem Cell & Regenerative Medicine USA Congress in Cambridge, Massachusetts (September 30–October 1), and the ColdChainIQ 11th Annual GDP & Temperature Management Logistics Global Forum in Chicago, Illinois (September 30–October 4).

Mr. O’Donnell will share his expertise on the challenges of moving high value biologics at ultra cold temperatures from the manufacturer to the patient bedside—in clinical trials as well as in the commercial marketplace. This will include an overview of how product packaging and clinical trial design can complicate logistics, add expense, and limit the number of clinical sites available for conducting phase II and phase III clinical trials. He will use a case study format to illustrate the technical challenges of meeting FDA requirements while moving products around the world at cryogenic temperatures, and share his experience with both autologous and allogeneic cell-based therapies.

Industry professionals who’d like to learn more about the latest end-to-end cell therapy solutions from Fisher BioServices can register for Mr. O’Donnell’s webinar - “Ultra Cold Chain & Logistical Challenges in Cell Therapy Clinical and Commercial Development” on October 10th, 2013. As Fisher BioServices’ Associate Director of Cell Therapy Logistics, Mr. O’Donnell has worked with numerous clients and assisted them in designing and implementing their ultra cold chain strategies which include packaging, qualified shipping systems, and patient delivery mechanisms that are cost-effective and align with patient safety needs and FDA requirements. He brings extensive experience and insight to the process of commercialization and distribution of biological therapeutics. Mr. O’Donnell’s webinar will include his insights and address some of the topics in his recent eBook, Commercially Successful Cell Therapies: Navigating the Ultra Cold Chain Distribution Minefield. Attendees will have the opportunity to ask questions. Mr. O’Donnell’s eBook is available at blog.fisherbioservices.com. To learn more or register for the webinar, go to http://connect.fisherbioservices.com/webinar/cell_therapy_webinar_clinical_trials_commercialization

About Fisher BioServices

Fisher BioServices has 28 years of experience in biorepository/biobanking services, cold chain logistics, and related support services for health-related research. The company manages high value biological specimens, cell-based therapeutics, vaccines, tissues, and related data in support of both clinical and public health research; they store and distribute more than 170,000,000 samples in more than 20 facilities worldwide for government, academic, and pharmaceutical clients. Fisher BioServices is part of Thermo Fisher Scientific Inc., the world leader in serving science.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of $13 billion, we have 39,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through three premier brands, Thermo Scientific, Fisher Scientific and Unity Lab Services, which offer a unique combination of innovative technologies, convenient purchasing options and a single solution for laboratory operations management. Our products and services help our customers solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Visit http://www.thermofisher.com.

Read the full story at http://www.prweb.com/releases/FisherBioServices/CellTherapy/prweb11089099.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Biotechnology Market (Biopharmacy, Bioservices, Bioagri, Bioindustrial) Is Expected to Reach USD 414.5 Billion Globally in 2017: Transparency Market Research
2. Generex Secures Commitments for $3.6M Capital Raise
3. K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan of Reorganization
4. Discovery Labs Receives $30 Million Funding Commitment from Deerfield Management
5. Dr. Carlos Szajnert, Announced today his Commitment to Further Educate his Patients on the Benefits of Cord Blood Stem Cells
6. VG Life Sciences, Inc. Secures Two-Year Funding Commitment and Administrative Support from MedBridge, LLC
7. Vital Imaging Makes Greater Commitment into MRI Research
8. Gene Therapy - Technologies, Markets and Companies
9. Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease
10. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
11. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Club. The event entitled “Stem Cells and Their Regenerative Powers,” was ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program ... honoring scientists who have made outstanding contributions to analytical chemistry and ... 2018, the world’s leading conference and exposition for laboratory science, which will be ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness Center ... the needs of consumers who are incorporating medical marijuana into their wellness and ... , As operators of two successful Valley dispensaries, The Giving Tree’s two founders, ...
Breaking Biology Technology:
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
Breaking Biology News(10 mins):